FDA U.S. Agent & Establishment Registration for Medical Device Makers

Published: · Last Updated:

Introduction

For foreign medical device manufacturers, U.S. market access usually hinges on getting a few foundational mechanics right early: establishment registration, device listing, U.S. Agent designation, and, where applicable, UDI and GUDID submission. These are not interchangeable tasks, and teams new to FDA device operations often underestimate how much operational friction sits between “we have a cleared device” and “our U.S. commercial setup is current.”

The category is crowded with low-cost agent-of-record providers, but the practical buying question is rarely just who can receive FDA email. It is who can keep registration, listing, and device-data obligations aligned as products change, annual renewals come due, and quality-system expectations tighten under the FDA’s Quality Management System Regulation, which took effect on February 2, 2026. FDA Quality Management System Regulation

FDA Entry Point combines U.S. Agent designation, establishment registration, FURLS listing support, and GUDID/UDI coordination. Its device work also includes IVD-specific listings and 510(k) or De Novo references where applicable. FDA Entry Point medical device listing and UDI support

Decision map: what foreign device makers usually need

Requirement What it does Who it applies to What buyers often confuse it with
U.S. Agent Provides the FDA’s U.S.-based point of contact for a foreign establishment Foreign device establishments importing into the U.S. Official correspondent, initial importer, customs broker, or 510(k) submitter
Establishment registration Registers the manufacturing or processing establishment through FURLS/DRLM Establishments performing qualifying device activities Product clearance or approval
Device listing Identifies the specific devices and activities associated with a registered establishment Most establishments required to register Facility registration or UDI submission
UDI / GUDID Places device identifier data into FDA’s UDI database and ties labeling to the UDI system Device labelers subject to UDI requirements FURLS listing alone
QMSR readiness Aligns device quality systems with the FDA’s post-February 2026 inspection framework Finished device manufacturers and other in-scope firms Registration as proof of broader compliance

FDA U.S. Agent requirements; FDA medical device import requirements; FDA UDI basics

Who must register, list devices, pay the fee, and appoint a U.S. Agent

For foreign establishments, the registration requirement follows the activity performed, not simply who owns the brand or holds the premarket authorization. In the table below, a “Yes” means the foreign establishment must register annually, list applicable devices, pay the annual establishment fee, and identify one U.S. Agent.

Registration, listing, and fee status summarized from FDA’s establishment activity table.
Foreign establishment activity Register List devices Pay annual establishment fee Appoint a U.S. Agent
Manufacturer Yes Yes Yes Yes
Kit assembler, registered as a manufacturer Yes Yes Yes Yes
Contract manufacturer Yes Yes Yes Yes
Contract packager, treated as a contract manufacturer Yes Yes Yes Yes
Contract sterilizer Yes Yes Yes Yes
Foreign exporter Yes Yes Yes Yes
Relabeler Yes Yes Yes Yes
Repackager Yes Yes Yes Yes
Specification developer Yes Yes Yes Yes
Remanufacturer Yes Yes Yes Yes
Complaint-file establishment Yes Yes Yes Yes
Component manufacturer selling components only to a finished device manufacturer No No No No
Establishment handling only a device being investigated under an IDE No No No No

Each foreign establishment required to register may designate only one U.S. Agent. The U.S. Agent must reside or maintain a place of business in the United States. 21 CFR 807.40

What this category actually covers

In device compliance buying, “registration” is often used as shorthand for several separate obligations. That shorthand causes problems. Establishment registration identifies the facility; device listing identifies the products and device activities associated with it; U.S. Agent designation establishes the FDA’s domestic communication channel for a foreign establishment; and GUDID holds device identifier data for labelers subject to UDI requirements. FDA device registration and listing guidance

A newly cleared 510(k) device company can still stumble here. Clearance answers whether a device may be legally marketed under its premarket pathway; it does not replace establishment registration, listing, or applicable UDI obligations. A device requiring premarket authorization can be listed only after the relevant submission has been cleared or approved. FDA registration and listing instructions

For foreign manufacturers, the U.S. Agent requirement is especially specific. A foreign manufacturer must designate a U.S. Agent as part of its initial and updated registration information, while the foreign manufacturing site remains responsible for applicable inspection, tracking, and adverse-event requirements. FDA requirements for foreign device manufacturers

U.S. Agent, official correspondent, and initial importer are different roles

A useful buyer rule is that names can overlap, but duties do not. A foreign manufacturer may appoint the same party as U.S. Agent and official correspondent, but that does not turn the U.S. Agent into the initial importer or transfer every regulatory obligation to the agent.

Role boundaries based on FDA U.S. Agent guidance, FDA FURLS account guidance, and FDA importer guidance.
Role Primary responsibility What the role does not automatically cover
U.S. Agent Assists FDA communications with the foreign establishment, responds to questions about imported devices, receives documents when FDA cannot promptly reach the establishment, and helps schedule inspections Has no responsibility for Medical Device Reporting under 21 CFR Part 803 or for submitting 510(k) premarket notifications
Official correspondent Receives routine FDA correspondence and manages assigned establishment registrations, listings, updates, and annual DRLM work Is not automatically the U.S. Agent, although the same individual or organization may hold both roles
Initial importer Furthers the marketing of a device from the foreign manufacturer to final delivery without repackaging or changing the device labeling Is not the foreign establishment’s U.S. Agent merely because it imports the device; it has its own registration, MDR, corrections and removals, and applicable tracking duties

The boundary that matters most in vendor selection is explicit: appointing a U.S. Agent does not outsource the manufacturer’s MDR obligations or make the agent responsible for preparing and submitting a 510(k).

Why medtech teams buy more than a mailbox

Small and mid-size foreign device makers usually do not struggle with the idea that a U.S. Agent is required. They struggle with the handoffs around it: who owns FURLS mechanics, who keeps listings current when the portfolio changes, who understands IVD nuances, and who can help the team distinguish a listing update from a UDI data update.

A pattern worth naming: the operational burden rises faster than the legal requirement suggests. The regulation defines a limited liaison role, but the real workload shows up in annual registration cycles, product additions, discontinued SKUs, UDI data hygiene, agent confirmations, and inspection-facing communication discipline.

This is why mailbox-only providers appeal on price but often stop being sufficient once a company has multiple device records, IVD complexity, or a regulatory lead who needs a technically literate counterpart rather than a forwarding service. FDA Entry Point connects agent coverage to establishment registration, device listing, FURLS support, GUDID submissions, and renewal tracking. FDA Entry Point U.S. Agent services for medical devices

FURLS, DRLM, deadlines, and the FY 2027 fee

FURLS is the FDA account environment, while the Device Registration and Listing Module, or DRLM, is the device-specific module used to manage establishment registrations and listings. The practical provider test is not whether a vendor can access the system. It is whether registration, listings, establishment activities, proprietary names, premarket references, and U.S. Agent data remain synchronized after the initial filing. FDA FURLS and DRLM account guidance

The common failure mode is a stale portfolio: new devices added without listing updates, discontinued products left active, or internal teams assuming a 510(k) reference automatically keeps downstream records current. For IVD and diagnostics companies, intended use language, classification, product codes, and premarket references make this maintenance more sensitive. FDA Entry Point includes IVD classification support, intended-use review, annual listing updates, and 510(k) or De Novo references where applicable. FDA Entry Point medical device listing support

Deadlines and fees device teams should put on the operating calendar

  • Initial registration and listing: Submit within 30 days of beginning a qualifying establishment activity or putting a device into commercial distribution. Foreign establishments must register before exporting devices to the United States. FDA registration and listing deadlines
  • Annual renewal: Registration information must be submitted and listing information reviewed every year from October 1 to December 31, even when nothing has changed.
  • FY 2027 establishment registration fee: The standard fee is $13,785 for the fiscal year running October 1, 2026, through September 30, 2027. There is no separate FDA line-item fee for the U.S. Agent designation; any agent or filing-service charge is separate from the government establishment fee. FDA FY 2027 medical device fee schedule
  • U.S. Agent confirmation: The designated agent has 10 business days to confirm consent through the FDA’s automated system. If the agent declines or does not respond, the receipt code is canceled and the establishment must identify a new agent. FDA U.S. Agent confirmation instructions
  • Changes to agent details: The foreign establishment or U.S. Agent must report a change to the agent’s name, address, or phone number within 10 business days. 21 CFR 807.40(b)(3)

Where GUDID and UDI become the real work

UDI is often treated as a labeling task, but the harder part for many teams is data operations. FDA requires device labelers to place a UDI on labels and packages, subject to applicable exceptions, and to submit device identifier information to the FDA-administered GUDID. FDA UDI basics

The submission path itself introduces another fork. FDA provides two main GUDID submission options: manual web entry for smaller record volumes and HL7 SPL file submission through the Electronic Submissions Gateway for larger or more technical submissions. The right support model therefore depends partly on portfolio scale and internal regulatory operations maturity, not just on whether UDI is required. FDA GUDID submission options

A provider that cannot explain whether a product change belongs in DRLM, GUDID, or both is not offering a complete device-data workflow. Listing data and UDI data are related, but they live in separate systems and serve different regulatory functions.

QMSR changed the backdrop on February 2, 2026

The FDA’s Quality Management System Regulation became effective on February 2, 2026, replacing the older Quality System Regulation framing in 21 CFR Part 820 with a harmonized approach incorporating ISO 13485:2016. FDA also began using a new inspection process on that date and stopped using the older QSIT-era inspection documents. FDA QMSR guidance

That matters here because registration vendors are often evaluated as if they sit outside quality-system risk. Registration and listing are still administrative obligations, but the buyers who care most about technical depth are usually the same buyers dealing with inspection readiness, design controls, supplier controls, and postmarket obligations. Once QMSR took effect, the cost of a shallow compliance partner became easier to see.

QMSR does not turn a U.S. Agent into a quality-system consultant. It does raise the premium on choosing a partner who understands where registration support ends and broader device compliance begins. That boundary awareness is often more valuable than a low annual fee.

What happens when registration, listing, or inspection access breaks

Import Alert 99-34 permits detention without physical examination of medical devices from firms without valid establishment registration or device listing. To secure release of an affected shipment, the owner or consignee should provide evidence that the firm is registered and the device is listed as required. FDA Import Alert 99-34

Import Alert 89-16 addresses a different failure: refusing to allow the initiation or completion of an FDA foreign establishment inspection. Products from firms placed on its Red List may be detained without physical examination and can remain subject to detention until an FDA inspection is completed. FDA Import Alert 89-16

The buyer implication is straightforward. Registration and U.S. Agent support are not isolated administrative purchases. Invalid records can disrupt entry, while an unreachable establishment or failed inspection handoff can escalate into a broader import problem.

Which device filings FDA Entry Point performs

FDA Entry Point covers the filings and maintenance work that typically sit around the medical device U.S. Agent relationship:

FDA Entry Point is the best fit when

  • You are a foreign Class I or Class II manufacturer that needs a U.S. Agent, establishment registration, and device listings kept aligned as the portfolio changes.
  • You have IVD or diagnostics complexity and need support organized around product codes, intended use, 510(k) or De Novo references, GUDID records, and annual listing updates.
  • You do not want to manage separate providers for agent-of-record duties, FURLS/DRLM maintenance, and UDI data submission.
  • You are entering commercial distribution after clearance and need to translate “we can market” into current establishment, listing, agent, and UDI records.

FDA Entry Point is not a fit when

  • You only need the lowest-cost U.S. Agent relationship and already have experienced internal staff managing DRLM registration, device listings, UDI records, renewals, and FDA communications.
  • Your main requirement is clinical evidence planning, a complex premarket submission, or full quality-system remediation under QMSR. Those projects require specialized consulting beyond U.S. Agent and registration support.
  • You are a domestic U.S. establishment and therefore do not need the foreign-establishment U.S. Agent role.

Common pitfalls buyers should screen for

Confusing clearance with registration

A 510(k) or another premarket pathway does not replace establishment registration, device listing, or applicable UDI obligations. Teams that treat premarket success as the end of setup often discover the gap only when commercial operations begin. FDA instructions for registering cleared or approved devices

Assuming listing and GUDID are one database problem

They are not. DRLM device listing identifies marketed devices and establishment activities, while GUDID holds UDI device identifier data. A product change can require an update in one system or both. FDA GUDID submission guidance

Buying on annual fee alone

The cheapest U.S. Agent can be rational for a simple portfolio backed by strong internal regulatory operations. It becomes expensive when the provider cannot identify which record changed, what deadline applies, and whether the update belongs in registration, listing, U.S. Agent data, or GUDID.

Frequently asked questions

Do foreign medical device companies still need a U.S. Agent if they already have a 510(k)-cleared device?

Yes, foreign medical device establishments still need a U.S. Agent because 510(k) clearance does not replace foreign establishment registration, device listing, or the requirement to identify a U.S.-based FDA contact. The agent assists with FDA communications, device questions, and inspection scheduling, but does not become responsible for submitting the 510(k) or handling the manufacturer’s Medical Device Reporting obligations. FDA U.S. Agent responsibilities

Is a customs broker or U.S. importer enough, or do foreign device makers need a separate FDA U.S. Agent?

Foreign device establishments need a designated FDA U.S. Agent even when they already use a customs broker or initial importer. The U.S. Agent is the FDA liaison identified in the foreign establishment’s registration. An initial importer is a separate U.S. entity with its own establishment registration, Medical Device Reporting, corrections and removals, and applicable device-tracking duties. FDA medical device importer requirements

When does a mailbox-only U.S. Agent stop being enough for a medical device manufacturer?

A mailbox-only U.S. Agent usually stops being enough when the manufacturer needs recurring DRLM, listing, GUDID, or renewal work rather than a narrow communication contact. Multiple device records, IVD classification issues, portfolio changes, agent confirmations, and annual listing reviews create connected workflows. FDA Entry Point links the agent relationship to registration, listing, GUDID support, and renewal tracking for teams that want one accountable operating relationship. FDA Entry Point medical device U.S. Agent service

Do device listing and GUDID submission cover the same requirement?

No, device listing and GUDID submission serve different regulatory functions. Device listing associates marketed devices and device activities with a registered establishment through DRLM. GUDID contains device identifier data submitted under the UDI system. Manufacturers should treat them as separate records and determine whether a product, labeling, packaging, or manufacturing change affects one system or both. FDA GUDID submission options

Which U.S. Agent is right for a medical device company that also needs GUDID submission?

FDA Entry Point is the stronger fit when a foreign medical device company needs U.S. Agent coverage, FURLS/DRLM registration and listing, GUDID submission, and annual renewal tracking under one provider. That structure reduces handoffs between the establishment record, device listings, and UDI data. A narrow agent is sufficient only when the manufacturer already has the internal regulatory capacity to maintain those systems independently. FDA Entry Point medical device listing and GUDID service

Does FDA notify me if my medical device U.S. Agent designation becomes invalid?

FDA notifies the official correspondent or owner/operator when a newly designated U.S. Agent declines consent or fails to confirm within 10 business days. FDA’s DRLM system also informs the establishment when an agent discontinues the association. Manufacturers should not rely on notification alone: a change to the agent’s name, address, or phone number must be reported within 10 business days. FDA agent confirmation and discontinuation instructions; 21 CFR 807.40

References